Elanco in the news

Purdue University and Elanco are establishing the One Health Research Institute in Indianapolis to advance animal, plant, and human health innovation for farmers and livestock producers.

Elanco Animal Health exceeded Q2 2026 expectations with 8% organic constant currency revenue growth, driven by key product innovations and strong performance in U.S. Pet Health and Farm Animal segments, leading to an increased full-year outlook.

Purdue University and Elanco Animal Health Incorporated started construction on the One Health Research Institute, a new hub for collaborative research and innovation in animal, human, and plant health.

Elanco Animal Health's anchor role in the new One Health Research Institute with Purdue University could enhance its R&D and long-term profitability by fostering innovation in animal, human, and environmental health.

Elanco and Purdue University are collaborating to establish the One Health Research Institute in Indianapolis to accelerate innovation in animal agriculture.

Elanco launched Eluracat, a new oral solution for cats with chronic conditions to stimulate appetite and promote weight gain.

Elanco and Purdue University are building the One Health Research Institute in West Indianapolis, a research facility within the One Health Innovation District, to foster collaboration between academia and industry for product development in human and animal health.

Elanco and Purdue University are partnering to create a research and development institute in Indiana, focusing on critical areas like antimicrobial resistance and vaccine development, backed by substantial investment from both Elanco and the state.

An Elanco executive acquired deferred stock units on October 2, 2026, increasing their holdings to over 9,900 units.

This document contains a list of Elanco Animal Health Incorporated (ELAN) call options data, including strike prices, last prices, and trading metrics, with data delayed by 15 minutes.

Elanco's CFO acquired 8.8988 deferred stock units at $22.14 per unit on October 2, 2026.

Elanco Animal Health and Purdue University broke ground on the One Health Research Institute in Indianapolis to innovate in animal, human, plant, and environmental health and strengthen the food supply chain.

KeyBanc reiterated an Overweight rating for Elanco Animal Health due to strong Q2 2026 earnings, positive clinic demand for parasiticides, and an upcoming Q3 earnings call on November 6, 2026.

Elanco Animal Health's stock is considered undervalued at $22.14, with a fair value of $31.21, despite recent short-term declines, as the company implements operational changes for financial stability.

KeyBanc reiterated an Overweight rating on Elanco Animal Health, citing strong product adoption, increased parasiticide prescriptions, and better-than-expected Q2 2026 earnings.

Elanco provides innovative solutions for animal health and well-being, as a global leader in the industry.

A director at Elanco acquired over 600 deferred stock units by deferring cash fees.

KeyBanc reiterated its "Overweight" rating and $30 price target on Elanco Animal Health due to strong parasiticide trends and product adoption.

KeyBanc reiterated an Overweight rating with a $30.00 price target on Elanco Animal Health.

Elanco Animal Health's stock increased following raised full-year guidance and strong second-quarter results that surpassed estimates.